Holdings presented data supporting rademikibart, the Company’s investigational, next-generation, potentially best-in-class anti-interleukin-4-receptor alpha antibody, at the European Respiratory ...
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies.1 Icotrokinra also showed ...
Background Hospitalisation with acute heart failure (AHF) carries a high risk of death, and those surviving to discharge ...
Novartis will launch a direct-to-patient (DTP) platform in the US on November 1, 2025, starting with Cosentyx, which will be offered at a 55% dis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback